Published in Am J Med on August 01, 1973
Pyoverdin is essential for virulence of Pseudomonas aeruginosa. Infect Immun (1996) 3.51
Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages. J Clin Invest (1975) 2.04
Evaluation of a new polyvalent Pseudomonas vaccine in respiratory infections. Infect Immun (1979) 1.61
Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun (1994) 1.52
Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia. Infect Immun (1986) 1.37
Interaction of Pseudomonas aeruginosa alkaline protease and elastase with human polymorphonuclear leukocytes in vitro. Infect Immun (1984) 1.34
Generation and characterization of murine antiflagellum monoclonal antibodies that are protective against lethal challenge with Pseudomonas aeruginosa. Infect Immun (1990) 1.17
A three-year study of nosocomial infections associated with Pseudomonas aeruginosa. J Clin Microbiol (1983) 1.07
A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide. Infect Immun (1991) 1.00
Selective inhibition of the accumulation of extracellular proteases of Pseudomonas aeruginosa by gentamicin and tobramycin. Antimicrob Agents Chemother (1985) 0.99
Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide. J Clin Invest (1986) 0.99
Granulocyte transfusion therapy of experimental Pseudomonas pneumonia. J Clin Invest (1974) 0.97
Clinical and pharmacological studies of ticarcillin in gram-negative infections. Antimicrob Agents Chemother (1976) 0.95
Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother (1993) 0.95
Pseudomonas elastase acts as a virulence factor in burned hosts by Hageman factor-dependent activation of the host kinin cascade. Infect Immun (1989) 0.94
Retracted Essential role of transcription factor nuclear factor-kappaB in regulation of interleukin-8 gene expression by nitrite reductase from Pseudomonas aeruginosa in respiratory epithelial cells. Infect Immun (1999) 0.93
Protective effect of Lactobacillus casei on Pseudomonas aeruginosa infection in mice. Infect Immun (1985) 0.93
Effects of a human antiflagellar monoclonal antibody in combination with antibiotics on Pseudomonas aeruginosa infection. Antimicrob Agents Chemother (1992) 0.86
Effects of the combination of lipopolysaccharide-specific monoclonal antibodies and sparfloxacin against Pseudomonas aeruginosa pneumonia in neutropenic mice. Antimicrob Agents Chemother (1992) 0.83
Nitrite reductase from Pseudomonas aeruginosa released by antimicrobial agents and complement induces interleukin-8 production in bronchial epithelial cells. Antimicrob Agents Chemother (1999) 0.78
Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia. Antimicrob Agents Chemother (1985) 0.77
Therapy of Pseudomonas aeruginosa infections with tobramycin. Antimicrob Agents Chemother (1975) 0.77
Thin-section CT findings in Pseudomonas aeruginosa pulmonary infection. Br J Radiol (2012) 0.77
Infectious diseases: annual review of significant publications. Postgrad Med J (1974) 0.75
Epidemiology of Pseudomonas aeruginosa in a general hospital: a four-year study. J Clin Microbiol (1975) 0.75
Pseudomonas pneumonia in status asthmaticus. Postgrad Med J (1977) 0.75
Inhibitory effect of Pseudomonas aeruginosa on phagocytosis and killing of rabbit polymorphonuclear leukocytes. Infect Immun (1980) 0.75
Polymicrobial septicemia due to Shigella flexneri and pseudomonas aeruginosa: first report. J Natl Med Assoc (1987) 0.75
Use of cephalosporins in the immunologically compromised patient. Drugs (1987) 0.75
[Pseudomonas aeruginosa immunoglobulin in experimental pneumonia]. Infection (1987) 0.75
Preparation and characterisation of Punica granatum pericarp aqueous extract loaded chitosan-collagen-starch membrane: role in wound healing process. J Mater Sci Mater Med (2015) 0.75
Comparison of high-resolution computed tomography findings between Pseudomonas aeruginosa pneumonia and Cytomegalovirus pneumonia. Eur Radiol (2014) 0.75
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res (1971) 13.16
Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) (1970) 5.98
Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med (1970) 5.03
Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med (1976) 4.85
Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis (1990) 4.75
Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J Lab Clin Med (1974) 4.31
Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest (1977) 4.21
Assessment of response to therapy in advanced breast cancer. Br J Cancer (1977) 3.70
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med (1992) 3.54
Bronchoalveolar lavage. Am Rev Respir Dis (1987) 2.87
Receptors for immunoglobulin and complement on human alveolar macrophages. J Immunol (1975) 2.74
Alveolar macrophage-derived chemotactic factor: kinetics of in vitro production and partial characterization. J Clin Invest (1980) 2.50
Hodgkin's disease. Immunologic, clinical, and histologic features of 50 untreated patients. Ann Intern Med (1967) 2.38
Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med (1978) 2.36
Ectopic production of human chorionic gonadotrophin by neoplasms. Ann Intern Med (1973) 2.30
Pulmonary host defenses. I. Analysis of protein and lipids in bronchial secretions and antibody responses after vaccination with pseudomonas aeruginosa. J Immunol (1973) 2.25
Mechanism for the inflammatory response in primate lungs. Demonstration and partial characterization of an alveolar macrophage-derived chemotactic factor with preferential activity for polymorphonuclear leukocytes. J Clin Invest (1977) 2.24
Fat metabolism in insects. Annu Rev Nutr (2001) 2.19
Endomyocardial disease and eosinophilia. A clinical and pathologic spectrum. Am J Med (1969) 2.13
Collagenase in the lower respiratory tract of patients with idiopathic pulmonary fibrosis. N Engl J Med (1979) 2.13
Evaluation of Pseudomonas aeruginosa exotoxin A and elastase as virulence factors in acute lung infection. Infect Immun (1983) 2.06
Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages. J Clin Invest (1975) 2.04
Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst (1990) 1.97
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol (2001) 1.94
Pulmonary host defenses. II. Interaction of respiratory antibodies with Pseudomonas aeruginosa and alveolar macrophages. J Immunol (1973) 1.92
Intestinal lymphangiectasia: a protein-losing enteropathy with hypogammaglobulinemia, lymphocytopenia and impaired homograft rejection. J Clin Invest (1967) 1.88
Penetration of antibiotics into respiratory secretions. Rev Infect Dis (1981) 1.86
Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest (1984) 1.86
Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis. Am J Med (1975) 1.81
Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy. Antimicrob Agents Chemother (1981) 1.81
Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators. J Clin Oncol (1994) 1.79
Pathogenesis of Pseudomonas aeruginosa pneumonia during immunosuppression. J Infect Dis (1978) 1.74
Immunity to experimental cholera. I. Protective effect of humoral IgG antitoxin demonstrated by passive immunization. J Immunol (1974) 1.73
Pseudohyperkalemia due to release of potassium from white blood cells during clotting. N Engl J Med (1966) 1.73
A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer (1978) 1.71
Summary of infectious complications occurring in patients with Hodgkin's disease. Cancer Res (1966) 1.62
Evaluation of a new polyvalent Pseudomonas vaccine in respiratory infections. Infect Immun (1979) 1.61
Recovery of cytomegalovirus from adults with neoplastic disease. Ann Intern Med (1966) 1.58
Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay. J Clin Invest (1981) 1.57
Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients. J Infect Dis (1991) 1.50
Extrapulmonary small-cell carcinoma. A review of the literature with emphasis on therapy and outcome. Medicine (Baltimore) (1987) 1.50
Influence of mucoid coating on clearance of Pseudomonas aeruginosa from lungs. Infect Immun (1981) 1.49
Pneumonia in the intensive care unit setting. J Intensive Care Med (1993) 1.48
Comparison of bacterial adherence to ciliated and squamous epithelial cells obtained from the human respiratory tract. Am Rev Respir Dis (1983) 1.47
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol (1987) 1.42
Secretory component deficiency. A disorder of the IgA immune system. N Engl J Med (1976) 1.41
Mucoid Escherichia coli in cystic fibrosis. N Engl J Med (1981) 1.37
Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med (1980) 1.37
Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia. Infect Immun (1986) 1.37
Active immunization with lipopolysaccharide Pseudomonas antigen for chronic Pseudomonas bronchopneumonia in guinea pigs. J Clin Invest (1981) 1.35
Lipopolysaccharide pseudomonas vaccine: efficacy against pulmonary infection with Pseudomonas aeruginosa. J Infect Dis (1979) 1.35
Infection in lymphoma. Histology, treatment, and duration in relation to incidence and survival. JAMA (1966) 1.34
Cancer treatment and age: patient perspectives. J Natl Cancer Inst (1993) 1.34
Limitations of using urea to quantify epithelial lining fluid recovered by bronchoalveolar lavage. Am Rev Respir Dis (1987) 1.34
Special report. Steriod receptors in breast cancer. N Engl J Med (1979) 1.33
Enhancement of the antitumor effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and cyclophosphamide by vitamin A. J Natl Cancer Inst (1972) 1.32
Treatment of Burkitt's tumor with cyclophosphamide. Cancer (1970) 1.29
L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med (1969) 1.29
In vitro growth of normal and leukemic human bone marrow. J Natl Cancer Inst (1971) 1.27
Gallium-67 citrate scanning in the staging of idiopathic pulmonary fibrosis: Correlation and physiologic and morphologic features and bronchoalveolar lavage. Am Rev Respir Dis (1978) 1.27
Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother (1984) 1.26
Clinical implications of cytogenetic variants in chronic myelocytic leukemia (CML). Blood (1968) 1.26
Elevated antibody titers to Epstein-Barr virus in Hodgkin's disease. Cancer (1971) 1.25
IgG proteolytic activity of Pseudomonas aeruginosa in cystic fibrosis. J Infect Dis (1985) 1.25
Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am J Med (1967) 1.25
Concentrations of gentamicin and carbenicillin in bronchial secretions. J Infect Dis (1973) 1.23
Gentamicin sulfate pharmacokinetics: lower levels of gentamicin in blood during fever. J Infect Dis (1975) 1.22
Complement biosynthesis by human bronchoalveolar macrophages. Clin Immunol Immunopathol (1983) 1.21
Lipid storage and mobilization in insects: current status and future directions. Insect Biochem Mol Biol (2001) 1.21
Immunity to experimental cholera. II. Secretory and humoral antitoxin response to local and systemic toxoid administration. J Infect Dis (1975) 1.20
Comparison of antibiotic regimens for treatment of experimental pneumonia due to Pseudomonas. J Infect Dis (1979) 1.19
Mucoid Pseudomonas aeruginosa. A sign of cystic fibrosis in young adults with chronic pulmonary disease? JAMA (1976) 1.19
A simple, single-step technique for selecting and cloning hybridomas for the production of monoclonal antibodies. J Immunol Methods (1982) 1.18
Immunoglobulin G subclass proteins in serum and lavage fluid of normal subjects. Quantitation and comparison with immunoglobulins A and E. Am Rev Respir Dis (1985) 1.18
Central nervous system involvement in Burkitt's lymphoma. Blood (1970) 1.16
Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids. Cancer Res (1968) 1.16
The health consequences of smoking. Cancer. Med Clin North Am (1992) 1.15
Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer (1983) 1.14
Hematologic and cytogenetic remission of blastic transformation in chronic granulocytic leukemia. Blood (1971) 1.14
Characterization of lymphocytes in bronchial lavage fluid from monkeys. J Immunol (1976) 1.14
Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. Eur J Cancer (1978) 1.13
Experimental pneumonia due to Haemophilus influenzae: observations on pathogenesis and treatment. J Infect Dis (1984) 1.13
Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer (1978) 1.13
Use of Pseudomonas aeruginosa lipopolysaccharide immunoadsorbents to prepare high potency, mono-specific antibodies. J Immunol Methods (1980) 1.12
Aspergillus pneumonia in hematologic malignancy. Improvements in diagnosis and therapy. Arch Intern Med (1977) 1.11
Dose-dependent effect of glucocorticosteroids on pulmonary defenses in a steroid-resistant host. Am Rev Respir Dis (1982) 1.11
A lesson from the mammography issue. Ann Intern Med (1978) 1.11
Structural units of canine serum and secretory immunoglobulin A. Biochemistry (1971) 1.11
Lymphoma of the breast. Ann Surg (1981) 1.11
Respiratory infection complicating long-term tracheostomy. The implication of persistent gram-negative tracheobronchial colonization. Chest (1984) 1.10
Isolation and partial characterization of a human alveolar macrophage-derived neutrophil-activating factor. J Clin Invest (1985) 1.10
Early trypsin, a female-specific midgut protease in Aedes aegypti: isolation, aminoterminal sequence determination, and cloning and sequencing of the gene. Insect Biochem Mol Biol (1996) 1.09
Ampicillin versus cefamandole as initial therapy for community-acquired pneumonia. Antimicrob Agents Chemother (1987) 1.08
Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res (1965) 1.08
Development of cellular and humoral immunity in the respiratory tract of rabbits to Pseudomonas lipopolysaccharide. J Clin Invest (1974) 1.08